These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22333262)

  • 1. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer.
    Haber SL; McNatty D
    Ann Pharmacother; 2012 Mar; 46(3):419-23. PubMed ID: 22333262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
    Andrici J; Tio M; Eslick GD
    Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
    Kharazmi M; Persson U; Warfvinge G
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-induced osteonecrosis of the jaw.
    Krueger CD; West PM; Sargent M; Lodolce AE; Pickard AS
    Ann Pharmacother; 2007 Feb; 41(2):276-84. PubMed ID: 17299010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bisphosphonates and oesophageal cancer.
    Wysowski DK
    BMJ; 2010 Sep; 341():c4506. PubMed ID: 20813821
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonate adverse effects, lessons from large databases.
    Abrahamsen B
    Curr Opin Rheumatol; 2010 Jul; 22(4):404-9. PubMed ID: 20473174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reports of esophageal cancer with oral bisphosphonate use.
    Wysowski DK
    N Engl J Med; 2009 Jan; 360(1):89-90. PubMed ID: 19118315
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More on reports of esophageal cancer with oral bisphosphonate use.
    Abrahamsen B; Eiken P; Eastell R
    N Engl J Med; 2009 Apr; 360(17):1789; author reply 1791-2. PubMed ID: 19387022
    [No Abstract]   [Full Text] [Related]  

  • 15. Bisphosphonate-associated adverse events.
    Papapetrou PD
    Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More on reports of esophageal cancer with oral bisphosphonate use.
    Siris ES; Oster MW; Bilezikian JP
    N Engl J Med; 2009 Apr; 360(17):1791; author reply 1791-2. PubMed ID: 19391259
    [No Abstract]   [Full Text] [Related]  

  • 19. More on reports of esophageal cancer with oral bisphosphonate use.
    Hofbauer LC; Miehlke S
    N Engl J Med; 2009 Apr; 360(17):1790; author reply 1791-2. PubMed ID: 19391258
    [No Abstract]   [Full Text] [Related]  

  • 20. More on reports of esophageal cancer with oral bisphosphonate use.
    Shaheen NJ
    N Engl J Med; 2009 Apr; 360(17):1790-1; author reply 1791-2. PubMed ID: 19391257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.